Abstract
Since many drug-drug pharmacokinetic interactions are dependent on the concentrations of the interacting species, the degree of interaction should be a graded phenomenon varying with drug and/or metabolite concentration and thus drug administration and time. Hence one should be able to develop predictive kinetic models for such interactions. A change in drug plasma levels when a compound is administered as a single dose together with another drug can arise from a change drug clearance, displacement from binding sites, a change in elimination rates, or a combination of any or all of these possibilities. The interaction of phenobarbital and the sparingly soluble oral antifungal agent, griseofulvin, is one example. Analysis shows that there is no change in elimination half- life of griseofulvin but that phenobarbital reduces the extent of griseofulvin absorption rather than enhances its elimination. Sulfaphenazole inhibits the metabolism and markedly prolongs tolbutamide plasma levels. An anticipated sudden drop in the excretion rate of the tolbutamide metabolites at maximum sulfonamide plasma levels is associated with an almost complete block of tolbutamide oxidation. The inhibitor constant K1 for this interaction has been calculated, allowing one to predict tolbutamide and metabolite levels when the inhibitor is administered. Drug- drug interaction resulting from protein displacement has been hypothesized by a number of authors. However, the potentiation of the anticoagulant warfarin in patients receiving phenylbutazone is more complicated than has been envisioned previously. While displacement occurs, data suggest that phenylbutazone primarily acts through selective inhibition to alter the isomeric composition and potency of the racemic warfarin administered. The warfarin- phenylbutazone interaction study stresses the importance of measuring metabolites as well as intact drug.
Similar content being viewed by others
References
L. F. Prescott. Pharmacokinetic drug interactions.Lancet (N. Am. Ed.) 11: 1239–1243 (1969).
H. F. Morelli. Drug interactions. InClinical Pharmacology (K. H. Melmon and H. F. Morrelli, eds.), MacMillan Press, Washington, 1970, Chap. 17, pp. 585–604.
R. A. Branch, D. G. Shand, C. R. Wilkinson, and A. S. Nies. The deduction of lidocaine clearance byd l propranolol-An example of hemodynamic drug interaction.J. Pharmacol. Exptl. Therap. 184: 515–519 (1973).
A. G. MacGregor. Symposium 7. Clinical effects of interaction between drugs.Proc. Royal Soc. Med. 58: 943–946 (1965).
K. Melmon, H. F. Morelli, J. A. Oates, A. H. Conney, T. N. Tozer, B. P. Harpole, and T. H. Clark. Drug interactions that affect your patient.Patient Care 1: 32–71 (1967).
E. A. Hartshorn. Drug interaction.Drug Intelligence 2: 174–180 (1968).
D. L. Azarnoff and A. Hurwitz. Drug interactions.Pharmacology for Physicians 4: No. 2 (1970).
P. D. Hansten.Drug Interactions, 2nd ed., Lea & Febiger, Philadelphia, 1973.
E. W. Martin.Hazards of Medication. J. B. Lippincott, Philadelphia, 1971.
J. G. Wagner. Pharmacokinetics.Ann. Rev. Pharmacol. 8: 67–93 (1968).
G. Levy. Kinetics of pharmacologic effects.Clin. Pharmacol. Therap. 7: 362–372 (1966).
G. Levy and M. Gibaldi. Pharmacokinetics of drug action.Ann. Rev. Pharmacol. 12: 85–97 (1972).
G. Levy and C. Regardh. Drug biotransformation interactions in man. V. Acetaminophen and salicylic acid.J. Pharm. Sci. 60: 608–611 (1971).
G. Levy and H. Yamada. Drug biotransformation interactions in man. III. Acetaminophen and salicylamide.J. Pharm. Sci. 60: 215–221 (1971).
E. M. Sellers and J. Koch-Weser. Kinetic and clinical importance of displacement of warfarin from albumin by acidic drugs.Ann. N. Y. Acad. Sci. 179: 213–225 (1971).
D. Bushfield, K. J. Child, and R. M. Atkinson. An effect of phenobarbitone on blood levels of griseofulvin in man.Lancet 2: 1042–1043 (1963).
S. Riegelman, M. Rowland, and W. L. Epstein. Griseofulvin-phenobarbital interaction in man.JAMA 213: 426–431 (1970).
P. M. Aggeler and R. A. O'Reilly. Effect of heptabarbital on the response to bishydroxy-coumarin in man.J. Lab. Clin. Med. 74: 229–238 (1970).
L. K. Christensen. Drug induced changes of the blood glucose lowering effect of oral hypoglycemic agents. InPharmacology and Mode of Oral Hypoglycemic Agents, Vol. VI (A. Loubatieres and A. E. Rengold, eds.), Casa Editrice “Il Ponte,” Milano, 1969, pp. 116–136.
D. A. Hussar. The hypoglycemic agents-Their interactions.J. Am. Pharm. Ass. NS 10: 619–624 (1970).
R. C. Thomas and C. J. Ikeda. The metabolic fate of tolbutamide in man and in the rat.J. Med. Chem. 9: 507–512 (1966).
E. Schulz and F. H. Schmidt. Abbanhemmung von Tolbutamide durch Sulfaphenazol beim Menschen.Pharmacol. Clin. 2: 150–152 (1970).
L. K. Christensen, J. M. Hansen, and M. Kristensen. Sulfaphenazole induced hypoglycemic attacks in tolbutamide treated diabetes.Lancet 2: 1298–1301 (1963).
W. Riess, K. Schmid, and H. Keberle. Über den Stoffwechsel von Sulfaphenazol.Klin. Wschr. 43: 740–744 (1965).
S. B. Matin, J. Karam, and M. Rowland. Kinetics of drug-drug interaction: Tolbutamide-sulfaphenazole interaction in man.J. Pharmacokin. Biopharm. (submitted).
J. R. Gillette. Techniques for studying drug metabolismin vitro. InFundamentals of Drug Metabolism (B. N. La Du, H. G. Mandel, and E. L. Way, eds.), Williams and Wilkins, Baltimore, 1971, Chap. 19, pp. 400–418.
L. J. P. Duncan and J. D. Baird. Oral insulin substitutes.Scot. Med. J. 2: 171–182 (1957).
M. Rowland. Drug administrations and regimens. InClinical Pharmacology (K. H. Melmon and H. F. Morrelli, eds.), MacMillan Press, New York, 1972, Chap. 2, pp. 21–60.
J. G. Wagner, J. I. Northam, C. D. Alway, and O. S. Carpenter. Blood levels of drug at the equilibrium state after multiple dosing.Nature 207: 1301–1302 (1965).
U. C. Dubach, A. Burke, and J. Raaflaub. Einfluss von Sulfonamiden auf die blutzucker-senkende Wirkung oral Antidiabetika.Schweiz. Med. Wschr. 96: 1483–1486 (1966).
E. G. McQueen and W. M. Wardell. Drug displacement from protein binding; Isolation of a redistributional drug interactionin vivo.Brit. J. Pharmacol. 43: 312–324 (1971).
M. Rowland, P. Thomson, K. H. Melmon, and A. Guichard. The disposition kinetics of lidocaine in man.Ann. N. Y. Acad. Sci. 179: 383–398 (1971).
P. M. Aggeler, R. A. O'Reilly, L. Leong, and P. Kowitz. Potentiation of anticoagulant effect of warfarin by phenylbutazone.New Engl. J. Med. 276: 496–501 (1967).
H. M. Solomon and J. J. Schrogie. The effect of various drugs on the binding of warfarin-14C to human albumin.Biochem. Pharmacol. 16: 1219–1226 (1967).
R. J. Lewis, W. F. Trager, K. K. Chan, A. Breckenridge, and M. Orme. Stereochemical considerations of the metabolism of warfarin in man. Studies with the R and S isomer.J. Clin. Invest. (in press).
Author information
Authors and Affiliations
Additional information
Much of the work reported in this paper was supported by a grant from the National Institutes of Health, Bethesda, Maryland, NIGMS 16496.
This paper was presented by Dr. Rowland at the Conference on Pharmacology and Pharma-cokinetics; Problems and Perspectives, October 30–November 1, 1972, at the Fogarty International Center, National Institutes of Health, Bethesda, Maryland. This paper, in a slightly different format, will be published in the Proceedings of the Conference by Plenum Press, New York.
Rights and permissions
About this article
Cite this article
Rowland, M., Matin, S.B. Kinetics of drug-drug interactions. Journal of Pharmacokinetics and Biopharmaceutics 1, 553–567 (1973). https://doi.org/10.1007/BF01059791
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059791